М. В. Копп

1.4k total citations
16 papers, 359 citations indexed

About

М. В. Копп is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, М. В. Копп has authored 16 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in М. В. Копп's work include Colorectal Cancer Treatments and Studies (5 papers), Neutropenia and Cancer Infections (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). М. В. Копп is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Neutropenia and Cancer Infections (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). М. В. Копп collaborates with scholars based in Russia, United States and Spain. М. В. Копп's co-authors include Oleg Gladkov, Cathy Eng, Vladimir Vladimirov, Vladimir Moiseyenko, Johanna C. Bendell, Ching Hsu, Brian Schwartz, Ellen Bolotin, Reinhard von Roemeling and Sandro Barni and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

М. В. Копп

15 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
М. В. Копп Russia	11	188	102	98	84	56	16	359
Hitomi Suzuki Japan	9	111 0.6×	117 1.1×	99 1.0×	106 1.3×	50 0.9×	43	459
Frank Seebach United States	9	166 0.9×	106 1.0×	92 0.9×	64 0.8×	80 1.4×	37	407
Yingcheng Lin China	9	191 1.0×	90 0.9×	85 0.9×	143 1.7×	62 1.1×	32	436
Akinari Morinaga Japan	10	108 0.6×	87 0.9×	97 1.0×	79 0.9×	68 1.2×	25	312
Go Ohira Japan	11	255 1.4×	58 0.6×	74 0.8×	107 1.3×	140 2.5×	53	413
Carlo Barone Italy	13	210 1.1×	66 0.6×	200 2.0×	35 0.4×	66 1.2×	20	394
Katia Dotti Italy	12	364 1.9×	91 0.9×	149 1.5×	58 0.7×	99 1.8×	28	514
Guo Long China	13	170 0.9×	213 2.1×	152 1.6×	91 1.1×	60 1.1×	26	492
Norifumi Iseda Japan	13	171 0.9×	147 1.4×	159 1.6×	104 1.2×	125 2.2×	54	498
Sanders Chang United States	11	114 0.6×	138 1.4×	74 0.8×	62 0.7×	109 1.9×	25	417

Countries citing papers authored by М. В. Копп

Since Specialization

Citations

This map shows the geographic impact of М. В. Копп's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by М. В. Копп with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites М. В. Копп more than expected).

Fields of papers citing papers by М. В. Копп

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by М. В. Копп. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by М. В. Копп. The network helps show where М. В. Копп may publish in the future.

Co-authorship network of co-authors of М. В. Копп

This figure shows the co-authorship network connecting the top 25 collaborators of М. В. Копп. A scholar is included among the top collaborators of М. В. Копп based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with М. В. Копп. М. В. Копп is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Орлова, Р. В., et al.. (2021). Практические рекомендации по лечению анемии при злокачественных новообразованиях. Malignant tumours. 10(3s2-2). 17–23. 3 indexed citations

Kaidarova, Dilyara, М. В. Копп, Vadim S. Pokrovsky, et al.. (2019). Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy. Oncology Letters. 18(5). 5644–5652. 10 indexed citations

Folprecht, Gunnar, Carles Pericay, Mark Saunders, et al.. (2016). Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Annals of Oncology. 27(7). 1273–1279. 61 indexed citations

Eng, Cathy, Alberto Bessudo, Lowell L. Hart, et al.. (2016). A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy. International Journal of Cancer. 139(1). 177–186. 52 indexed citations

Nechaeva, Marina, Olga Burdaeva, Vladimir Vladimirov, et al.. (2015). Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study.. Journal of Clinical Oncology. 33(15_suppl). e20735–e20735. 5 indexed citations

Krivorotko, Petr, et al.. (2015). Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy. SHILAP Revista de lepidopterología. 17(2). 45–52. 1 indexed citations

Orlov, Sergey, Olga Burdaeva, М. В. Копп, et al.. (2015). Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: Results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC.. Journal of Clinical Oncology. 33(15_suppl). 8057–8057. 16 indexed citations

Burdaeva, Olga, et al.. (2014). Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients.. Journal of Clinical Oncology. 32(15_suppl). e11576–e11576. 11 indexed citations

Orlov, Sergey, Olga Burdaeva, М. В. Копп, et al.. (2014). Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients.. Journal of Clinical Oncology. 32(15_suppl). e13500–e13500. 11 indexed citations

10.

Cohn, Allen Lee, Josep Tabernero, Joan Maurel, et al.. (2013). A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Annals of Oncology. 24(7). 1777–1785. 74 indexed citations

11.

Eng, Cathy, Lowell L. Hart, Oleg Gladkov, et al.. (2013). A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.. Journal of Clinical Oncology. 31(15_suppl). 3508–3508. 22 indexed citations

12.

Melichar, Bohuslav, Daniil Stroyakovskiy, Jin Seok Ahn, et al.. (2012). Pathological Complete Response to Trastuzumab Subcutaneous Fixed-Dose Formulation in the Hannah Study: Subgroup Analysis of Patient Demographics and Tumor Characteristics and Influence of Body Weight (BW) and Serum Trough Concentration (Ctrough) of Trastuzumab. Annals of Oncology. 23. ix97–ix98. 3 indexed citations

13.

Hesketh, Paul J., Oliver Wright, Gerardo Rosati, et al.. (2011). Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Supportive Care in Cancer. 20(7). 1471–1478. 26 indexed citations

14.

Bessudo, Alberto, Johanna C. Bendell, N. Gabrail, et al.. (2011). Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy.. Journal of Clinical Oncology. 29(15_suppl). 3582–3582. 13 indexed citations

15.

Peterson, Douglas E., Ірина Давиденко, М. В. Копп, et al.. (2009). Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Recombinant Human Intestinal Trefoil Factor Oral Spray for Prevention of Oral Mucositis in Patients With Colorectal Cancer Who Are Receiving Fluorouracil-Based Chemotherapy. Journal of Clinical Oncology. 27(26). 4333–4338. 51 indexed citations

16.

Novik, Andrei A., Tatyana Ionova, Alexander Myasnikov, et al.. (2005). Quality of Life (QoL) Impairment and International Prognostic Index (IPI) in New Aggressive Non-Hodgkin’s Lymphoma (ANHL) Patients.. Blood. 106(11). 4651–4651.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact